Modulatory efficacy of hesperetin (citrus flavanone) on xenobiotic-metabolizing enzymes during 1,2-dimethylhydrazine-induced colon carcinogenesis

被引:26
作者
Aranganathan, S. [1 ]
Selvam, J. Panneer [1 ]
Sangeetha, N. [1 ]
Nalini, N. [1 ]
机构
[1] Annamalai Univ, Dept Biochem & Biotechnol, Annamalainagar 608002, Tamil Nadu, India
关键词
Hesperetin; Aberrant crypt foci; Dimethylhydrazine; Xenobiotics; ABERRANT CRYPT FOCI; RAT COLON; LIPID-PEROXIDATION; LIVER-MICROSOMES; AZOXYMETHANE; REDUCTASE; PURIFICATION; INDUCTION; ASSAY;
D O I
10.1016/j.cbi.2009.03.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer is the second leading cause of cancer death worldwide with diet playing a prominent role in disease initiation and progression. Diet and nutrition play an important role during this multi-step colon carcinogenic process. We have investigated the modulatory efficacy of hesperetin on aberrant crypt foci (ACF) and xenobiotic-metabolizing enzymes on 1,2-dimethylhydrazine (DMH)-induced colon carrinogenesis. Male albino Wistar rats were randomly divided into six groups. Group 1 served as control, received modified pellet diet and group 2 rats received 20 mg/kg body weight of hesperetin p.o. every day. Groups 3-6 rats were given subcutaneous injections of 1,2-dimethylhydrazine (20 mg/kg body weight) once a week for 15 weeks to induce ACF in the colon. In addition, rats in group 4 received hesperetin as in group 2 orally for the first 15 weeks (initiation), group 5 rats received hesperetin as in group 2 after the last injection of DMH and continued till the end of the experimental period (post-initiation). Group 6 received hesperetin as in group 2 throughout the entire period of 32 weeks. DMH exposure showed high incidence (90%) of ACF (280 +/- 24.5 aberrant crypt/colon) and dysplastic ACF, elevated activities of phase I enzymes and reduced the activities of phase 11 enzymes in the liver and colonic mucosa of colon cancer bearing rats. Hesperetin supplementation significantly reversed these effects, the effect being more pronounced in group 6 rats (hesperetin supplemented throughout the study period). These findings suggest that hesperetin can significantly reduce the formation of preneoplastic lesions and effectively modulate the xenobiotic-metabolizing enzymes in rats. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:254 / 261
页数:8
相关论文
共 47 条
[1]   DNA damage and aberrant crypt foci as putative biomarkers to evaluate the chemopreventive effect of annatto (Bixa orellana L.) in rat colon carcinogenesis [J].
Agner, AR ;
Bazo, AP ;
Ribeiro, LR ;
Salvadori, DMF .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2005, 582 (1-2) :146-154
[2]   Hesperetin exerts dose dependent chemopreventive effect against 1,2-dimethyl hydrazine induced rat colon carcinogenesis [J].
Aranganathan, Selvaraj ;
Selvam, Jayabal Panneer ;
Nalini, Namasivayam .
INVESTIGATIONAL NEW DRUGS, 2009, 27 (03) :203-213
[3]   Phenobarbital and 3-methylcholanthrene treatment alters phase I and II enzymes and the sensitivity of the rat colon to the carcinogenic activity of azoxymethane [J].
Baijal, PK ;
Fitzpatrick, DW ;
Bird, RP .
FOOD AND CHEMICAL TOXICOLOGY, 1997, 35 (08) :789-798
[4]   ROLE OF ABERRANT CRYPT FOCI IN UNDERSTANDING THE PATHOGENESIS OF COLON-CANCER [J].
BIRD, RP .
CANCER LETTERS, 1995, 93 (01) :55-71
[5]   Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer [J].
Cai, YZ ;
Luo, Q ;
Sun, M ;
Corke, H .
LIFE SCIENCES, 2004, 74 (17) :2157-2184
[6]  
Cheng L, 2003, WORLD J GASTROENTERO, V9, P2642
[7]  
CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO
[8]  
2-P
[9]   Evaluation of hesperetin 7-O-lauryl ether as lipid-lowering agent in high-cholesterol-fed rats [J].
Choi, GS ;
Lee, S ;
Jeong, TS ;
Lee, MK ;
Lee, JS ;
Jung, UJ ;
Kim, HJ ;
Park, YB ;
Bok, SH ;
Choi, MS .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (13) :3599-3605
[10]   Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma [J].
Dasgupta, RK ;
Adamson, PJ ;
Davies, FE ;
Rollinson, S ;
Roddam, PL ;
Ashcroft, AJ ;
Dring, AM ;
Fenton, JAL ;
Child, JA ;
Allan, JM ;
Morgan, GJ .
BLOOD, 2003, 102 (07) :2345-2350